Head-to-head evidence
Pegaptanib (Macugen) vs RGX-314
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Pegaptanib (Macugen)
Marketed by Pfizer
NCT01100307 · Phase 3 · completed
This was a randomized, double-masked, sham-controlled phase 3 trial with 243 participants and a hard clinical visual-acuity endpoint. The primary endpoint was met: 25 of 123 participants receiving pegaptanib versus 6 of 120 receiving sham achieved at least a 10-letter improvement at week 24 (p=0.0003).
RGX-314
Developed by REGENXBIO Inc.
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pegaptanib (Macugen)'s landscape · RGX-314's landscape